Izinova (Magnesium Sulfate Heptahydrate, Sodium Sulfate Anhydrous, Potassium Sulphate)

Izinova provides mineral salts that support electrolyte homeostasis and osmotic activity in the gastrointestinal tract.

• Electrolyte replenishment: restores magnesium, sodium and potassium levels in patients with deficiency or loss due to illness or treatment.
• Constipation relief: the osmotic action of sulfate salts draws water into the bowel, facilitating stool passage.
• Prevention of hypomagnesemia: supplies magnesium to reduce risk of muscle cramps and cardiac arrhythmias in at‑risk individuals.

• After oral ingestion, magnesium sulfate, sodium sulfate and potassium sulfate dissociate into their respective ions (Mg2+, Na+, K+ and SO4²‑). The cations contribute to systemic electrolyte pools, supporting neuromuscular function, cardiac conduction and fluid balance. Sulfate anions act osmotically in the intestinal lumen, increasing intraluminal water content and promoting bowel motility, while also participating in biochemical pathways such as sulfation reactions.

Izinova may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild stomach upset after ingestion.
• Abdominal cramping: discomfort due to osmotic activity.
• Diarrhea: loose stools from increased intestinal water.
• Headache: occasional mild headache.
• Dizziness: transient light‑headedness.
• Metallic taste: brief aftertaste.

Serious or Rare Side Effects

• Hypermagnesemia: elevated magnesium levels causing muscle weakness or cardiac effects.
• Hyperkalemia: excess potassium leading to arrhythmias.
• Severe electrolyte imbalance: significant shifts in sodium or potassium.
• Anaphylactic reaction: rare allergic response with rash, swelling, or breathing difficulty.
• Severe hypotension: marked drop in blood pressure.
• Acute renal failure: in patients with pre‑existing kidney disease.

When considering Izinova, clinicians should evaluate patient-specific factors and monitor for safety.

• Assess baseline electrolyte levels: ensure magnesium, sodium and potassium are within normal range before initiation.
• Monitor renal function: impaired kidneys may reduce clearance of the salts.
• Avoid in severe renal impairment: risk of accumulation and toxicity.
• Use caution with cardiac conduction disorders: electrolyte shifts can affect rhythm.
• Do not combine with other osmotic laxatives: may cause excessive fluid loss.
• Store at ambient temperature: keep in the original pack, protect from moisture.

Izinova can interact with several medicines that affect electrolyte balance or neuromuscular transmission.

Major Interactions (Avoid)

• Neuromuscular blocking agents: potentiates muscle relaxation.
• Calcium channel blockers: additive hypotensive effect.
• Tetracycline antibiotics: reduced absorption of the antibiotic.
• Potassium‑sparing diuretics: risk of hyperkalemia.
• ACE inhibitors: may enhance potassium retention.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may increase electrolyte loss.
• Other mineral supplements: monitor total intake to avoid excess.
• Antacids containing aluminum or magnesium: possible additive gastrointestinal effects.
• NSAIDs: may affect renal handling of electrolytes.
• Oral contraceptives: monitor for altered potassium levels.